Search Within

Nicole Lamanna

Formats
  1. Meeting Abstract (39)
  2. Journal Article (19)
  3. Book Section (2)
Groups
  1. Center for Hematologic Malignancies (35)
  2. Department of Medicine (35)
  3. Hematologic Malignancies, Division of (35)
  4. Adult Leukemia (23)
  5. GSK Faculty (19)
  6. Hematologic Malignancies Research (19)

More Groups

People
  1. Mark Weiss (24)
  2. Peter Maslak (18)
  3. Joseph Jurcic (17)
  4. David Scheinberg (13)
  5. Mark Heaney (12)
  6. Renier Brentjens (12)

More People

Years
  1. 2015 (1)
  2. 2014 (7)
  3. 2013 (7)
  4. 2012 (9)
  5. 2011 (4)
  6. 2010 (2)

More Years

Publications
  1. Blood (19)
  2. Journal of Clinical Oncology (15)
  3. Current Hematologic Malignancy Reports (5)
  4. Current Oncology Reports (2)
  5. Haematologica (2)
  6. Advances in Pharmacology (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. American Society of Clinical Oncology (15)
  3. Springer (7)
  4. American Association for Cancer Research (2)
  5. CMP Healthcare Media (2)
  6. Elsevier Inc. (2)

More Publishers

Results (60)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results
    Meeting Abstract

    Munir, T.; Hillmen, P.; Eradat, H.; Ghia, P.; O'Brien, S.; Furman, R.; Coutre, S.; Sharman, J.; Cheson, B.; Pagel, J.; more...
    British Journal of Haematology (2015)

    Fulltext@MSK | Save
  • A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely of idelalisib on eninhination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia
    Meeting Abstract

    Salles, G. A.; Lamanna, N.; Amin, B. R.; Boccia, R. V.; Gabrali, N. Y.; Zaydan, M. A. A.; Wong, M.; Adewoye, A. H.; Ghia, P.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results
    Meeting Abstract

    Ghia, P.; O'Brien, S. M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL
    Meeting Abstract

    Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • The Warburg effect confers adverse outcome in chronic lymphocytic leukemia
    Meeting Abstract

    Gardner, J. R.; Devlin, S. M.; Knapp, K.; Bauli, F.; Patel, M.; Lamanna, N.; Frattini, M. G.; Brentjens, R.; Maslak, P.; Jurcic, J. G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save
  • Health-related quality of life impact of idelalisib (idela) in patients with relapsed chronic lymphocytic leukemia (cll): Phase 3 results
    Meeting Abstract

    Eradat, H. A.; Ghia, P.; O'Brien, S. M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Barrientos, J. C.; more...
    Haematologica (2014)

    Fulltext@MSK | Save
  • Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed cll
    Meeting Abstract

    Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; more...
    Haematologica (2014)

    Fulltext@MSK | Save
  • A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of biib021 administered orally in patients with advanced solid tumors
    Journal Article

    Saif, M. W.; Takimoto, C.; Mita, M.; Banerji, U.; Lamanna, N.; Castro, J.; O'Brien, S.; Stogard, C.; Hoff, D. V.
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Meeting Abstract

    O'Brien, S. M.; Lamanna, N.; Kipps, T. J.; Flinn, I.; Zelenetz, A. D.; Burger, J. A.; Holes, L.; Johnson, D. M.; Gu, J.; Dansey, R. D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3Kδ, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): Effect of del(17p)/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation
    Meeting Abstract

    Coutre, S. E.; Leonard, J. P.; Barrientos, J. C.; De Vos, S.; Flinn, I.; Furman, R. R.; Brown, J. R.; Wagner-Johnston, N.; Benson, D. M. Jr; Schreeder, M. T.; more...
    Blood (2013)

    Fulltext@MSK | Save